Across TCGA pan-cancer cohorts, KRTAP3-2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KRTAP3-2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher KRTAP3-2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KRTAP3-2 expression acts as an unfavorable survival marker.

BRCA, COAD, and SKCM are the cancer types where KRTAP3-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.514	0.963	<.001	36	view →
COAD	DFS	Median	III,IV	0.170	0.697	.030	6	view →
SKCM	OS	Median	III,IV	0.255	0.840	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KRTAP3-2 tumor-vs-normal RNA expression · all KRTAP3-2 data types